{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:19:16Z","timestamp":1792275556266,"version":"4.4.0"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,3,29]],"date-time":"2020-03-29T00:00:00Z","timestamp":1585440000000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,3,3]]},"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs). Although the incidence and prevalence of irAEs have been well characterized in the literature, less is known about the cumulative incidence rate of irAEs. We studied the cumulative incidence of irAEs, defined as the probability of irAE occurrence over time and the risk factors for irAE development in metastatic urothelial carcinoma (mUC) and renal cell carcinoma (mRCC) patients treated with ICIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We identified a cohort of patients who received ICIs for mUC and mRCC. irAEs were classified using Common Terminology Criteria for Adverse Event (CTCAE) V.5.0 guidelines. The monthly incidence of irAEs over time was reported after landmark duration of therapy. Cumulative incidence of irAEs was calculated to evaluate the time to the first occurrence of an irAE accounting for the competing risk of death. Prognostic factors for irAE were assessed using the Fine and Gray method.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 470 patients were treated with ICIs between July 2013 and October 2018 (mUC: 199 (42.3%); mRCC: 271 (57.7%)). 341 (72.6%) patients received monotherapy, 86 (18.3%) received ICIs in combination with targeted therapies, and 43 (9.2%) received dual ICI therapy. Overall, 186 patients (39.5%) experienced an irAE at any time point. Common irAEs included hypothyroidism (n=42, 22.6%), rush and pruritus (n=36, 19.4%), diarrhea\/colitis (n=35, 18.8%), transaminitis (n=32, 17.2%), and pneumonitis (n=14, 7.5%). Monthly incidence rates decreased over time; however, 17 of 109 (15.6%, 95% CI: 9.4% to 23.8%) experienced their first irAE at least 1\u2009year after treatment initiation. No differences in cumulative incidence were observed based on cancer type, agent, or irAE grade. On multivariable analysis, combined ICI therapy with another ICI or with targeted therapy (p&lt;0.001), first-line ICI therapy (p=0.011), and PD-1 inhibitor therapy (p=0.007) were all significantly associated with irAE development.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study quantitates the incidence of developing irAEs due to ICI conditioned on time elapsed without irAE development. Although the monthly incidence of irAEs decreased over time on therapy, patients can still develop delayed irAEs beyond ICI discontinuation, and thus, continuous vigilant monitoring is warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2019-000371","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T05:44:25Z","timestamp":1585633465000},"page":"e000371","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5618-8079","authenticated-orcid":false,"given":"Pier Vitale","family":"Nuzzo","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R","family":"Pond","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Abou Alaiwi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8084-9105","authenticated-orcid":false,"given":"Amin H","family":"Nassar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Flippot","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Curran","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L","family":"Kilbridge","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao X","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley A","family":"McGregor","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni","family":"Choueiri","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-1588","authenticated-orcid":false,"given":"Lauren C","family":"Harshman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,3,30]]},"reference":[{"key":"2025100304570334000_8.1.e000371.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4226"},{"key":"2025100304570334000_8.1.e000371.2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.critrevonc.2019.04.008","article-title":"Efficacy and safety of combination immunotherapy for malignant solid tumors: a systematic review and meta-analysis","volume":"138","author":"Wei","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025100304570334000_8.1.e000371.3","doi-asserted-by":"publisher","DOI":"10.1038\/nm730"},{"key":"2025100304570334000_8.1.e000371.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1514296"},{"key":"2025100304570334000_8.1.e000371.5","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(95)90125-6"},{"key":"2025100304570334000_8.1.e000371.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2025100304570334000_8.1.e000371.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025100304570334000_8.1.e000371.8","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z"},{"key":"2025100304570334000_8.1.e000371.9","first-page":"5671","article-title":"Immune-Related adverse events during anticancer immunotherapy: pathogenesis and management","volume":"14","author":"Stucci","year":"2017","journal-title":"Oncol Lett"},{"key":"2025100304570334000_8.1.e000371.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.0105"},{"key":"2025100304570334000_8.1.e000371.11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27969"},{"key":"2025100304570334000_8.1.e000371.12","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0645-6"},{"key":"2025100304570334000_8.1.e000371.13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.10.017","article-title":"Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials","volume":"107","author":"Kanjanapan","year":"2019","journal-title":"Eur J Cancer"},{"key":"2025100304570334000_8.1.e000371.14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00354.x"},{"key":"2025100304570334000_8.1.e000371.15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.it.2016.11.007","article-title":"Autoimmune cardiotoxicity of cancer immunotherapy","volume":"38","author":"Cheng","year":"2017","journal-title":"Trends Immunol"},{"key":"2025100304570334000_8.1.e000371.16","doi-asserted-by":"publisher","DOI":"10.1038\/nature01621"},{"key":"2025100304570334000_8.1.e000371.17","doi-asserted-by":"publisher","DOI":"10.1038\/ng1020"},{"key":"2025100304570334000_8.1.e000371.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"2025100304570334000_8.1.e000371.19","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr695"},{"key":"2025100304570334000_8.1.e000371.20","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0455-8"},{"key":"2025100304570334000_8.1.e000371.21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2017.00056","article-title":"Incidence of immune-related adverse events with program death receptor-1- and program death receptor-1 ligand-directed therapies in genitourinary cancers","volume":"7","author":"Maughan","year":"2017","journal-title":"Front Oncol"},{"key":"2025100304570334000_8.1.e000371.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"2025100304570334000_8.1.e000371.23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/TCRM.S193338","article-title":"Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients","volume":"15","author":"Zhou","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"2025100304570334000_8.1.e000371.24","doi-asserted-by":"crossref","unstructured":"Wang Y , Zhou S , Yang F , et al . Treatment-Related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol 2019;5.doi:10.1001\/jamaoncol.2019.0393","DOI":"10.1001\/jamaoncol.2019.0393"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2019-000371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:57:14Z","timestamp":1759492634000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2019-000371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3,30]]},"published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1136\/jitc-2019-000371"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2019-000371","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}